Ora Unveils Breakthrough Research in Ophthalmic Clinical Trials, New Blind Canvas Project Stories at ARVO 2026

BOSTON--(BUSINESS WIRE)--Ora, the leading global ophthalmic contract research organization (CRO), today announced the presentation of new scientific research at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3–7 in Denver, Colorado.

Ora’s poster presentations at ARVO 2026 showcase cutting-edge innovations designed to advance ophthalmic clinical trials, including artificial intelligence–driven image analysis, novel retinal endpoints supporting emerging therapeutics, and advanced technologies to deliver heightened precision with more accurate assessments of dry eye treatment efficacy. Attendees are invited to visit Ora at Booth #9015 to learn how Ora’s expert teams, rigorous processes, and innovative clinical approaches accelerate ophthalmic research worldwide.

“ARVO continues to set the global standard for showcasing the latest advancements in ophthalmic research, and Ora is thrilled to once again be part of this impactful congress in 2026,” said Paul Colvin, Chief Executive Officer of Ora. “For more than 50 years, Ora has been a trusted clinical trial partner to innovators around the world. Our scientific contributions at ARVO and our sponsorship of Eyecelerator® reflect our ongoing commitment to advancing innovative study designs, endpoints, and technologies that help bring critical new ophthalmic therapies to the patients who need them most.”

Ora is proud to serve as a Gold Sponsor of Eyecelerator @ ARVO 2026, a premier program spotlighting industry innovation, investment trends, and breakthrough products transforming eye care. In addition, Ora is excited to team up with Eyecelerator and Unither Pharmaceuticals to launch Eye to Market—a new video series dedicated to accelerating understanding of how ophthalmic innovations move from scientific insight to real-world adoption. Episode 1 will be launching May 1 on https://www.youtube.com/@eyecelerator.

Alongside scientific presentations at ARVO, Ora continues to elevate the patient perspective through The Blind Canvas Project, a collaborative initiative that shines a light on the human experience of blindness. Featuring new interviews and online gallery content from seven storytellers, the project helps deepen understanding and bridge communication between patients, researchers, and the broader community. Together, these stories reinforce Ora’s belief that meaningful progress in ophthalmology begins with a deeper understanding of the people research is ultimately intended to serve. To learn more, visit www.blindcanvasproject.com.

“The Blind Canvas Project celebrates resilience and the diversity of experiences within the blind community, fostering empathy, connection, and hope,” said Keith Lane, Chief Scientific Officer, Posterior Segment, Ora. “For Ora, it is a powerful reminder of why we place patients at the center of everything we do. Engaging directly with the community deepens our understanding of patient needs and challenges and helps us more effectively support the development of new drugs and devices that can meaningfully improve patients’ lives.”

Together, Ora’s ARVO research presentations, Eyecelerator sponsorship, Eye to Market launch, and Blind Canvas Project updates reflect a broader commitment to advancing ophthalmology through scientific innovation, industry collaboration, and deeper patient understanding. We look forward to connecting with attendees throughout the meeting. Please visit us at Booth #9015 and see below for Ora’s full ARVO 2026 research presentation schedule.

ARVO 2026 ORA RESEARCH PRESENTATION SCHEDULE

Title	Presenter	Date/Time	Presentation / Poster #
Tablet Based Optokinetic Nystagmus Visual Acuity Assessment: A Novel Approach for Low Vision Populations with Retinal or Optic Nerve Dysfunction	Keith Lane, MBA	May 4, 2026 11:15 AM to 1:00 PM MT	1795 - 0833
EyeCup Imaging System vs. Slit-lamp Biomicroscopy: Comparative Analysis of Conjunctival Image Quality and Clinical Grading Efficiency	Ethan Bensinger, PhD	May 6, 2026 2:00 PM to 3:45 PM MT	4550 - 0046
Cyan-Channel Conversion and Automated Quantitative Grading of Lissamine Green Staining Compared With Expert Clinical Graders	Mark Abelson, MD, CM, FRCS(C)	May 6, 2026 2:00 PM to 3:45 PM MT	4552 - 0048
Precision Characterization of Ocular Surface Response Using a Titratable Controlled Adverse Environment (CAE-HT) Model	Matt Chapin, MBA	May 6, 2026 2:00 PM to 3:45 PM MT	4551 - 0047

About Ora

Ora is the world’s leading full-service ophthalmic drug and device CRO with employees in over 20 countries around the world. For over 50 years, we have proudly helped our clients earn more than 90 product approvals. We support a wide array of innovators and organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora’s clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. For more information, please visit www.oraclinical.com and follow us on LinkedIn.